文献速递核素与放射性配体治疗神经核医学

225Ac-DOTATATE靶向α治疗在生长抑素受体阳性神经内分泌肿瘤中的进展

Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2025-07-03

本文综述225Ac-DOTATATE靶向α治疗在晚期高分化生长抑素受体阳性神经内分泌肿瘤中的研究进展,整合临床前模型与早期临床研究证据,强调其强效抗肿瘤活性和良好毒性特征,并讨论放射性核素供应、子体再分布、剂量学及监管等限制及新兴策略。

要点

  • 225Ac-DOTATATE靶向α治疗在常规β发射体PRRT难治的SSTR阳性NET中显现治疗前景。
  • 临床前与早期临床研究提示强效抗肿瘤疗效和良好毒性特征。
  • 面临放射性核素供应、反冲致子体再分布、剂量学挑战和监管障碍。

核心结论

  • 225Ac-DOTATATE靶向α治疗是晚期高分化SSTR阳性NET管理中有前景的治疗选择,尤其在常规β发射体PRRT难治患者中。
  • 随着该疗法迈向主流临床整合,学术界、产业界和监管机构的多学科协作对完善方案、优化安全性和扩大可及性至关重要。

研究设计与样本

  • 本文为综述,整合临床前模型和早期临床研究的现有证据,并总结正在开展的关键试验。

主要发现

  • 综述强调225Ac-DOTATATE靶向α治疗在晚期高分化SSTR阳性NET中具有强效抗肿瘤疗效和良好毒性特征的治疗前景。
  • 综述描述了改善螯合剂、SSTR拮抗剂以及串联或联合治疗等新兴策略。
  • 综述讨论了放射性核素供应限制、反冲诱导的子体再分布、剂量学挑战和监管障碍等关键局限性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 放射性核素供应受限。
  • 反冲诱导的子体再分布。
  • 剂量学面临挑战。
  • 存在监管障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

225Ac-DOTATATE-based targeted alpha therapy (TAT) is emerging as a transformative option in the management of advanced, well-differentiated, somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs), particularly in patients refractory to conventional β-emitter peptide receptor radionuclide therapy (PRRT). This review synthesizes current evidence from preclinical models and early-phase clinical studies, highlighting its therapeutic promise in terms of potent antitumor efficacy and favorable toxicity profile. We discuss the radiobiological and mechanistic advantages of α-particle therapy while also addressing key limitations such as radionuclide supply constraints, recoil-induced daughter redistribution, challenges in dosimetry, and regulatory hurdles. Emerging strategies including improved chelators, SSTR antagonists, and tandem or combination therapies are described. Key ongoing trials have also been summarized. As 225Ac-DOTATATE-based TAT progresses toward mainstream clinical integration, multidisciplinary collaboration across academia, industry, and regulatory bodies will be essential to refine protocols, optimize safety, and expand access.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chandekar KR, Bal C. Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors. Semin Nucl Med. 2025. PMID: 40615276. doi:10.1053/j.semnuclmed.2025.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。